CN108239150A - 抗pcsk9抗体及其用途 - Google Patents

抗pcsk9抗体及其用途 Download PDF

Info

Publication number
CN108239150A
CN108239150A CN201611210645.3A CN201611210645A CN108239150A CN 108239150 A CN108239150 A CN 108239150A CN 201611210645 A CN201611210645 A CN 201611210645A CN 108239150 A CN108239150 A CN 108239150A
Authority
CN
China
Prior art keywords
ser
val
thr
pro
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201611210645.3A
Other languages
English (en)
Chinese (zh)
Inventor
曾竣玮
E·克劳兰
J·P·贝尔克
缪小牛
张敏
N·博兰
刘晓林
俞德超
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics Suzhou Co Ltd
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Priority to CN201611210645.3A priority Critical patent/CN108239150A/zh
Priority to CA3047049A priority patent/CA3047049C/en
Priority to KR1020197021287A priority patent/KR102331021B1/ko
Priority to US16/473,245 priority patent/US11485795B2/en
Priority to EP17883464.4A priority patent/EP3560961A4/en
Priority to BR112019012648-1A priority patent/BR112019012648A2/pt
Priority to PCT/CN2017/118050 priority patent/WO2018113781A1/zh
Priority to JP2019534112A priority patent/JP7167027B2/ja
Priority to AU2017379048A priority patent/AU2017379048B2/en
Priority to CN201780080278.6A priority patent/CN110177810B/zh
Publication of CN108239150A publication Critical patent/CN108239150A/zh
Priority to JP2022164233A priority patent/JP2023002635A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96411—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
CN201611210645.3A 2016-12-24 2016-12-24 抗pcsk9抗体及其用途 Pending CN108239150A (zh)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CN201611210645.3A CN108239150A (zh) 2016-12-24 2016-12-24 抗pcsk9抗体及其用途
BR112019012648-1A BR112019012648A2 (pt) 2016-12-24 2017-12-22 anticorpo anti-pcsk9 e uso do mesmo
KR1020197021287A KR102331021B1 (ko) 2016-12-24 2017-12-22 항-pcsk9 항체 및 이의 용도
US16/473,245 US11485795B2 (en) 2016-12-24 2017-12-22 Anti-PCSK9 antibody and use thereof
EP17883464.4A EP3560961A4 (en) 2016-12-24 2017-12-22 ANTI-PCSK9 ANTIBODIES AND ITS APPLICATION
CA3047049A CA3047049C (en) 2016-12-24 2017-12-22 Anti-pcsk9 antibody and use thereof
PCT/CN2017/118050 WO2018113781A1 (zh) 2016-12-24 2017-12-22 抗pcsk9抗体及其用途
JP2019534112A JP7167027B2 (ja) 2016-12-24 2017-12-22 抗ｐｃｓｋ９抗体およびその使用
AU2017379048A AU2017379048B2 (en) 2016-12-24 2017-12-22 Anti-PCSK9 antibody and application thereof
CN201780080278.6A CN110177810B (zh) 2016-12-24 2017-12-22 抗pcsk9抗体及其用途
JP2022164233A JP2023002635A (ja) 2016-12-24 2022-10-12 抗ｐｃｓｋ９抗体およびその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611210645.3A CN108239150A (zh) 2016-12-24 2016-12-24 抗pcsk9抗体及其用途

Publications (1)

Publication Number Publication Date
CN108239150A true CN108239150A (zh) 2018-07-03

Family

ID=62624551

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201611210645.3A Pending CN108239150A (zh) 2016-12-24 2016-12-24 抗pcsk9抗体及其用途
CN201780080278.6A Active CN110177810B (zh) 2016-12-24 2017-12-22 抗pcsk9抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780080278.6A Active CN110177810B (zh) 2016-12-24 2017-12-22 抗pcsk9抗体及其用途

Country Status (9)

Country Link
US (1) US11485795B2 (https=)
EP (1) EP3560961A4 (https=)
JP (2) JP7167027B2 (https=)
KR (1) KR102331021B1 (https=)
CN (2) CN108239150A (https=)
AU (1) AU2017379048B2 (https=)
BR (1) BR112019012648A2 (https=)
CA (1) CA3047049C (https=)
WO (1) WO2018113781A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220062416A1 (en) * 2018-05-11 2022-03-03 Innovent Biologics (Suzhou) Co., Ltd. Preparation comprising anti-pcsk9 antibody and use thereof
WO2026082095A1 (en) * 2024-10-17 2026-04-23 Innovent Biologics (Suzhou) Co., Ltd. Compounds for treating metabolic disorders

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108239150A (zh) * 2016-12-24 2018-07-03 信达生物制药(苏州)有限公司 抗pcsk9抗体及其用途
CA3155065A1 (en) * 2019-09-19 2021-03-25 Innovent Biologics (Suzhou) Co., Ltd. Use of anti-pcsk9 antibody in method for preventing or treating cholesterol-related disease
IL292973B2 (en) * 2019-11-18 2026-03-01 Ad Pharmaceuticals Co Ltd Anti-PCSK9 antibody and its use
CN116983434B (zh) * 2023-09-28 2024-03-15 康霖生物科技（杭州）有限公司 用于基因治疗的核酸构建体及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR100978980B1 (ko) 2006-02-14 2010-08-30 엑손모빌 케미칼 패턴츠 인코포레이티드 엠씨엠-22계 분자체의 제조 방법
US7572618B2 (en) * 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
US8821865B2 (en) 2010-11-11 2014-09-02 Abbvie Biotechnology Ltd. High concentration anti-TNFα antibody liquid formulations
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
CN105001336A (zh) * 2014-04-18 2015-10-28 上海复旦张江生物医药股份有限公司 Pcsk9拮抗剂
WO2015200438A1 (en) 2014-06-24 2015-12-30 Eleven Biotherapeutics, Inc. High affinity antibodies against pcsk9
CN106084058B (zh) * 2015-07-15 2019-08-27 北京天广实生物技术股份有限公司 抗人pcsk9单克隆抗体
CN105348390B (zh) * 2015-10-26 2018-08-28 北京智仁美博生物科技有限公司 抗人pcsk9单克隆抗体
CN105801701B (zh) * 2016-03-31 2019-03-29 河北仁博科技有限公司 一种pcsk9抗体的重链和轻链可变区及其应用
CN108239150A (zh) 2016-12-24 2018-07-03 信达生物制药(苏州)有限公司 抗pcsk9抗体及其用途
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
CN110464842B (zh) 2018-05-11 2022-10-14 信达生物制药(苏州)有限公司 包含抗pcsk9抗体的制剂及其用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220062416A1 (en) * 2018-05-11 2022-03-03 Innovent Biologics (Suzhou) Co., Ltd. Preparation comprising anti-pcsk9 antibody and use thereof
WO2026082095A1 (en) * 2024-10-17 2026-04-23 Innovent Biologics (Suzhou) Co., Ltd. Compounds for treating metabolic disorders

Also Published As

Publication number Publication date
CA3047049A1 (en) 2018-06-28
WO2018113781A1 (zh) 2018-06-28
US20200087416A1 (en) 2020-03-19
AU2017379048B2 (en) 2020-08-27
JP2023002635A (ja) 2023-01-10
CN110177810B (zh) 2022-10-18
JP7167027B2 (ja) 2022-11-08
KR102331021B1 (ko) 2021-11-26
EP3560961A4 (en) 2020-12-23
JP2020506670A (ja) 2020-03-05
US11485795B2 (en) 2022-11-01
KR20190096411A (ko) 2019-08-19
CA3047049C (en) 2023-10-24
CN110177810A (zh) 2019-08-27
EP3560961A1 (en) 2019-10-30
AU2017379048A1 (en) 2019-07-25
BR112019012648A2 (pt) 2020-01-28

Similar Documents

Publication Publication Date Title
JP6923658B2 (ja) 抗ｃｄ４７抗体およびその使用
JP6120833B2 (ja) 抗Ａｘｌ抗体及びその使用
TWI545132B (zh) 人類化抗－ＴＡＵ（ｐＳ４２２）抗體及使用方法
KR102331021B1 (ko) 항-pcsk9 항체 및 이의 용도
JP6033293B2 (ja) 抗Ａｘｌ抗体及びその使用
WO2019184912A1 (zh) 抗cd47抗体及其用途
TW201307391A (zh) 抗－ｐｃｓｋ９抗體及其使用方法
JP7112659B2 (ja) 抗ｐｃｓｋ９抗体およびその使用
CN113453700B (zh) 拮抗剂
CN110464842A (zh) 包含抗pcsk9抗体的制剂及其用途
CN118047871A (zh) 一种靶向FRα的抗体或其抗原结合片段及其应用
WO2017118307A1 (zh) Pcsk9抗体、其抗原结合片段及其医药用途
KR20250004705A (ko) 항-tdp-43 결합 분자
HK40012556B (en) Anti-pcsk9 antibody and application thereof
HK40012556A (en) Anti-pcsk9 antibody and application thereof
HK40098220A (zh) 抗ddr2抗体及其用途
EA046377B1 (ru) Антитела к fgf19

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180703